We thus hypothesized that ZNF267 was a DLBCL facilitator and a worse prognosis biomarker for DLBCL patients, and the knockdown of ZNF267 could potentially attenuate DLBCL progression. This evidence concerns the gene ZNF267 and diffuse large B-cell lymphoma.